Results 41 to 50 of about 22,249,811 (294)

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

Journal of Hematology & Oncology, 2021
CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL).
Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie, Weidong Han   +10 more
doaj   +1 more source

Kinetics and binding affinities of anti-PD-1 antibody to human PD-1 determined by BLI.

, 2021
Kinetics and binding affinities of anti-PD-1 antibody to human PD-1 determined by BLI.
Chien-Hsin Ho (2211316), Chih-Hsiang Tu (1435027), Lisa Xiao (11890940), Yen-Hsiao Chen (11890943), Eugene Liu (1271409), Zhenyu Ji (6291644), Ou Li (101542), Yanling Wang (309043), Eric Zhang (4459516), Yunchih Cheng (11890934), Yi-Ting Mao (2613853), Peihua Lin (11890937), Shilong Fan (9625883), Min Li (12799), Sandra Chen (11890946), Ya-Chin Hsiao (288524), Weidong Jiang (468041), Chi-Ling Tseng (11681538), Yun-Ju Huang (9605739), Hassan Issafras (11681550), Shumin Yang (847715)   +20 more
core   +1 more source

Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report

Frontiers in Oncology, 2023
BackgroundGastric cancer (GC) is the third most common cause of cancer-related death in the world. Several clinical trials have proven that the use of PD-1/PD-L1 inhibitors can improve the survival of late-stage GC patients and is suggested in NCCN and ...
Qijun Wang, Qijun Wang, Qijun Wang, Qijun Wang, Qijun Wang, Zhewei Shen, Zhewei Shen, Zhewei Shen, Zhewei Shen, Zhewei Shen, Mengxi Ge, Jie Xu, Xin Zhang, Xin Zhang, Xin Zhang, Xin Zhang, Xin Zhang, Wei Zhu, Wei Zhu, Wei Zhu, Wei Zhu, Wei Zhu, Jie Liu, Wei Hua, Wei Hua, Wei Hua, Wei Hua, Wei Hua, Ying Mao, Ying Mao, Ying Mao, Ying Mao, Ying Mao   +32 more
doaj   +1 more source

DataSheet_1_Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1.pdf

, 2023
BackgroundGalectin-3 (Gal-3) is a β-galactoside-binding lectin that is highly expressed within the tumor microenvironment of aggressive cancers and has been suggested to predict a poor response to immune checkpoint therapy with the anti-PD-1 monoclonal ...
James A. Roper, Robert J. Slack, James A. Roper (7135268), Lynda Vuong (14940512), Lynda Vuong, Alison C. Mackinnon (11354112), Joseph Mabbitt, Fredrik R. Zetterberg, Ulf J. Nilsson (831832), Ian D. Holyer (11920195), Joseph Mabbitt (16890483), Fredrik R. Zetterberg (8217516), Ulf J. Nilsson, Anders Pedersen, Ian D. Holyer, Alison C. Mackinnon, Robert J. Slack (1981372), Anders Pedersen (249829)   +17 more
core   +1 more source

Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis

World Journal of Otorhinolaryngology-Head and Neck Surgery, 2022
Background PD‐1 and PD‐L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC). Methods Systematic review and meta‐analysis of PD‐1 and PD‐L1 inhibitors in HNSCC.
Dylan A. Levy, Jaimin J. Patel, Shaun A. Nguyen, W. Nicholas Jungbauer, David M. Neskey, Ezra E. W. Cohen, Chrystal M. Paulos, John A. Kaczmar, Hannah M. Knochelmann, Terry A. Day   +9 more
doaj   +1 more source

sj-docx-1-tam-10.1177_17588359231206274 – Supplemental material for Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience

, 2023
Supplemental material, sj-docx-1-tam-10.1177_17588359231206274 for Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience by Qingyan Liu, Rong ...
Yi Hu (58993), Lingling Li (427154), Gaokun Wang (17282060), Xuan Zheng (424907), Haitao Tao (462014), Xiaodong Jia (783460), Rong Li (72042), Shiyu Ji (7879220), Qingyan Liu (12512598)   +8 more
core   +1 more source

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)

Frontiers in Cellular and Infection Microbiology, 2019
In the present study, we determined the in vitro characteristics and binding interactions of chicken PD-1 (chPD-1) and PD-L1 (chPD-L1) and developed a panel of specific monoclonal antibodies against the two proteins.
Vishwanatha R. A. P. Reddy, William Mwangi, Yashar Sadigh, Venugopal Nair   +3 more
doaj   +1 more source

Image_2_Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma.jpeg

, 2022
PurposeWe aimed to investigate the restoration of CD8+PD-1+ T cells through adoptive T-cell therapy (ACT) in relation to the prognosis and the therapeutic response to anti-PD-1 in patients with advanced pancreatic cancer (APC).MethodsA total of 177 adult
Qian Zhu (191342), Guoliang Qiao (621641), Chang Xu (102022), Jing Zhao (21160), Yuguang Song (150393), Lefu Huang (12394798), Bing Liu (70818), Deliang Guo (192224), Yufeng Yuan (1850647), Shuo Wang (143908), Zheng Chen (49483), Zhiyong Yang (11266)   +11 more
core   +1 more source

PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy

Cancer Immunology, Immunotherapy, 2022
Abstract Background Programmed cell death protein 1 (PD-1) antibody has been approved for a variety of tumors, but its effective rate is unsatisfactory. New evidence suggests that mast cells are an important component of the tumor microenvironment and are associated with resistance to immunotherapy, but the underlying ...
Jun Li, Gang Peng, Kuikui Zhu, Xiaohua Jie, Yingzhuo Xu, Xinrui Rao, Yunhong Xu, Yunshang Chen, Biyuan Xing, Gang Wu, Liangliang Shi   +10 more
openaire   +2 more sources

Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis [PDF]

, 2022
Background Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major classes of immune checkpoint inhibitors that are increasingly used for cancer treatment.
Yunlong Xia, Gary Tse, Sharen Lee, Lei Yang, Jiandong Zhou, Tong Liu, Yuhui Zhang, Kelvin King Hei Bao, Ian Chi Kei Wong, Qingpeng Zhang, Ishan Lakhani, Wing Tak Wong   +11 more
core   +1 more source